Cervical cancer incidence higher in states with lower proportion of HPV vaccination rates
the ONA take:
According to new findings presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in San Antonio, Texas, researchers from the University of North Carolina Gillings School of Global Public Health in Chapel Hill, North Carolina, the number of adolescent girls receiving the human papillomavirus (HPV) vaccine is much lower in states with higher rates of cervical cancer and cervical cancer-related mortality.
Using the National Immunization Survey-Teen, researchers identified the rates of HPV vaccination in various states, and identified cervical cancer rates in the same states using the United States Cancer Statistics database. States with higher vaccination rates had lower cancer incidence rates and vice versa.
For example, in Massachusetts, 69% of adolescent girls have begun the HPV vaccination series and 6 per 100,000 women develop cervical cancer a year, whereas in Arkansas, 41% of adolescent girls have initiated HPV vaccination and 10 per 100,000 women develop cervical cancer a year. In addition, completion rates of the HPV vaccine course were higher in states where adolescents have higher levels of contact with the healthcare system.
The researchers suggest that more adolescent preventive health care may be needed to improve completion rates of the HPV vaccination series.
Number of adolescent girls receiving the HPV vaccine much lower in states with higher rates of cervical cancer.
The proportion of adolescent girls receiving human papillomavirus (HPV) vaccines was much lower in states with higher rates of cervical cancer incidence and mortality, according to data presented at the American Association for Cancer Research (AACR) conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Nov. 9–12.
HPV vaccines can prevent individuals from developing several types of cancer, including cervical, anal, vaginal, and vulvar cancers. "Cervical cancer incidence and mortality rates vary widely by state," said Jennifer L. Moss, MSPH, a doctoral student in the Department of Health Behavior at the University of North Carolina Gillings School of Global Public Health in Chapel Hill.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- MRD Negativity Associated With Prolonged Survival in Myeloma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|